Evaluation of a Fast Point-of-care Platform for Diabetes Care at Out-patient Clinics
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Diabetes
- Sponsor
- Taichung Veterans General Hospital
- Enrollment
- 222
- Locations
- 1
- Primary Endpoint
- Changes from baseline to the end of study in eGFR
- Status
- Active, not recruiting
- Last Updated
- 7 months ago
Overview
Brief Summary
Using a point-of-care (POC) platform, the investigators will investigate the effects of POC testing for glycated hemoglobin (HbA1c) and cystatin C at out-patient clinics on long-term diabetes outcomes.
Detailed Description
Laboratory testing for HbA1c and cystatin C is time-consuming, and healthcare providers often do not have update results when they evaluate outpatients with diabetes. A POC testing platform may help address this issue, and the investigators aim to examine its effects on diabetes outcomes.
Investigators
Jun-Sing Wang, MD, PhD
Director, Division of Endocrinology and Metabolism
Taichung Veterans General Hospital
Eligibility Criteria
Inclusion Criteria
- •Adults aged 18 to 80 receiving treatment and follow-up for diabetes at outpatient clinics of Taichung Veterans General Hospital, Taichung, Taiwan.
Exclusion Criteria
- •Past medical history of hemolytic anemia, hemoglobinopathies (sickle cell anemia HbS, fetal hemoglobin HbF), iron deficiency anemia, thalassemia, pernicious anemia, recent blood transfusions, acute bleeding requiring erythropoiesis-stimulating agents.
- •Chronic liver disease, cirrhosis, hyperbilirubinemia, asplenia (splenomegaly, splenectomy).
- •Hypertriglyceridemia (over 500 mg/dl), or alcoholism.
- •Thyroid dysfunction, active malignant tumors under treatment, HIV infection.
- •Long-term use (over three months) of steroids or cyclosporine.
- •Severe proteinuria (e.g., nephrotic syndrome), or a baseline eGFR \<60 ml/min/1.73 m².
Outcomes
Primary Outcomes
Changes from baseline to the end of study in eGFR
Time Frame: Observational follow up period of 3 years
Estimated glomerular filtration rate (eGFR) will be determined using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (Levey AS, et al. Ann Intern Med. 2009; 150: 604-12).
Secondary Outcomes
- Changes from baseline to the end of study in UACR(Observational follow up period of 3 years)